Tapimmune - TPIV

Tapimmune (TPIV)
http://www.tapimmune.com
Coverage: January 21, 2010 - March 21, 2010
Featured: January 21, 2010

Latest Newsletter Editions

spacer
Sat, May 22, 2010 @ 02:05 pm
There was a little relief rally on Friday after a fairly wicked week in the markets. Thursday's giant sell down felt like a "cash at any cost" down draft, with almost no regard for value. That's fine with me. These kinds of emotional, momentum driven markets present opportunities for those with the...
Tue, May 18, 2010 @ 10:05 am
A Busy Day- Comments on a Bunch of Stuff Frankly, it's a bit annoying. I wish these smaller companies could get their quarterly numbers out over a few week period in time, instead of all in one or two days at the absolute deadline. I just can't get quality commentary out fast enough for investors to...
Mon, Feb 1, 2010 @ 03:02 pm
Nothing Like a Cool $200 Million You might wonder who's got the cool $200 million, and what it has to do with today's edition of the OTC Journal. Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I said some positive developments would start to roll their way, and today's post close news...
Wed, Jan 27, 2010 @ 09:01 am
Two Beat Downs; Stand By I just wanted to publish a couple of quick notes on two stocks I've been covering and have made comments on recently. First on China Recycling Energy (CREG)- someone is selling the stock fairly ruthlessly with little regard for price. It started two days ago, and the stock is...
Thu, Jan 21, 2010 @ 01:01 pm
How The Immune System Fights Disease Our bodies have a miraculous capability. Our Immune System, through a complex network of cells and chemicals, has the ability to identify bad stuff and rapidly recruit an army to attack foreign invaders and kill them. T-Cells are the circus ring masters. The T-Cells...

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.15 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 3:05pm Bid x Ask Size: N/A
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.1500 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm): N/A
Volume: 0 EPS (ttm): -0.03
spacer [Chart]

Business Summary

spacer
TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others.

Disclosure

spacer
MarketByte LLC has purchased 400,000 shares of Tapimmune with a cost basis of 7.5 cents from a non affiliate shareholder. The shares are freely tradeable. This should be construed as a form of compensation and a conflict of interest. The aforementioned shares could be sold at anytime without prior notification.

Recent News Headlines

spacer
10-K for TapImmune, Inc.
Thu, 23 Apr 2015 00:10:06 GMT
TAPIMMUNE INC Financials
Tue, 21 Apr 2015 17:04:20 GMT
TAPIMMUNE INC Files SEC form 10-K, Annual Report
Wed, 15 Apr 2015 20:08:03 GMT
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
Mon, 30 Mar 2015 22:33:00 GMT
[PR Newswire] - SEATTLE, March 30, 2015 /PRNewswire/ -- TapImmune Inc . (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" ...
TAPIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers
Fri, 27 Mar 2015 20:38:27 GMT
TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015
Wed, 25 Mar 2015 13:58:00 GMT
[PR Newswire] - SEATTLE, Mar. 25, 2015 /PRNewswire/ -- TapImmune Inc . (OTCBB: TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious ...
TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
Thu, 19 Mar 2015 16:32:59 GMT
[at noodls] - 19 Mar SEATTLE, March 19, 2015 - TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company's Board of Directors. ... This is an abstract of the original ...
TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors
Thu, 19 Mar 2015 12:45:00 GMT
[PR Newswire] - SEATTLE, Mar. 19, 2015 /PRNewswire/ --TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company's Board of Directors. David brings 30 years of experience ...
TapImmune Receives $1,000,000 from Strategic Investor
Thu, 12 Mar 2015 15:38:59 GMT
[at noodls] - 10 Mar Investment bolsters immediate capital needs for progressing clinical programs SEATTLE, March 10, 2015 - TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a US$1 million investment from Eastern ...
TAPIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Tue, 10 Mar 2015 21:14:07 GMT
TapImmune Receives $1,000,000 from Strategic Investor
Tue, 10 Mar 2015 12:30:00 GMT
[PR Newswire] - SEATTLE, March 10, 2015 /PRNewswire/ -- TapImmune, Inc. (TPIV), is pleased to announce a US$1 million investment from Eastern Capital Limited under the same terms as the recent January 12, 2015 round of financing. Eastern Capital Limited will receive a standard 5-year warrant that, if exercised, would provide $7.5 million in funding and callable warrants that, under certain market conditions, will provide an additional $7.0 million in capital to TapImmune. Additional warrants, exercisable only to the extent the callable warrants are exercised or called, could provide the Company with a further $10.0 million in funding. H.C. Wainwright & Co. acted as exclusive placement agent for the transaction. In Phase 1 over 95% of patients in both Her2neu positive breast cancer and in folate receptor alpha positive ovarian cancer demonstrated positive immune responses to TapImmune's antigens. Success in these trials has provided a strong basis for progression to Phase 2. "We plan to initiate a Phase 2 clinical trial in triple negative breast cancer in the near future," said Wilson.
TapImmune Appoints John Bonfiglio as Strategic Advisor
Wed, 25 Feb 2015 20:10:50 GMT
[at noodls] - 25 Feb Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 - TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, ...
TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer
Wed, 25 Feb 2015 20:10:50 GMT
[at noodls] - 23 Feb SEATTLE, Feb. 23, 2015 - TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to ...
TapImmune Appoints John Bonfiglio as Strategic Advisor
Wed, 25 Feb 2015 13:45:00 GMT
[PR Newswire] - He was formerly President and CEO of Argos Therapeutics where he raised over $35 million dollars for the Company and led the company in a successful Phase 2 study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising (over $50 million) and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation's Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University.
TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer
Mon, 23 Feb 2015 13:45:00 GMT
[PR Newswire] - SEATTLE, Feb. 23, 2015 /PRNewswire/ -- TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune's clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies. These technologies have been evaluated in Phase I trials for safety and immune responses in women with breast or ovarian cancer.
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
Mon, 23 Feb 2015 07:32:54 GMT
[at noodls] - 19 Feb Seattle, WA & NY, NY - February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious ...
TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015
Mon, 23 Feb 2015 04:41:41 GMT
[at noodls] - 20 Feb Seattle, WA - February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, ...
TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015
Fri, 20 Feb 2015 14:00:00 GMT
[PR Newswire] - SEATTLE, Feb. 20, 2015 /PRNewswire/ -- TapImmune Inc . (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, ...
TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations
Thu, 19 Feb 2015 14:30:00 GMT
[PR Newswire] - After a competitive process, TapImmune determined PCG presented a team that was best matched for the Company's strategic growth plans. In addition, the PCG team presented strong knowledge of the Company's science and financial goals. Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We determined that Jeff Ramson and his team at PCG would be the best overall fit for us. PCG's senior team has strong contacts across key U.S. Capital Markets and extensive experience in Public and Social Media. As we move TapImmune's clinical projects forward, we welcome the team's advisory services.
TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials
Tue, 10 Feb 2015 12:01:00 GMT
[Marketwired] - TapImmune Inc. , the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing ...